Skip to main content
Prime Medicine, Inc. logo

Prime Medicine, Inc. — Investor Relations & Filings

Ticker · PRME ISIN · US74168J1016 US Manufacturing
Filings indexed 260 across all filing types
Latest filing 2024-03-01 Capital/Financing Update
Country US United States of America
Listing US PRME

About Prime Medicine, Inc.

https://primemedicine.com/

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of one-time, curative genetic therapies. The company's approach is centered on its proprietary Prime Editing platform, a next-generation gene editing technology. Prime Editing is designed to function like a precise 'search and replace' mechanism for the genome, capable of correcting a wide range of disease-causing genetic mutations. It can perform insertions, deletions, and all types of point mutations without inducing double-strand DNA breaks, a key differentiator from some earlier gene editing techniques. The company's mission is to address the root genetic cause of debilitating diseases, aiming to provide patients with potentially lifelong therapeutic benefits.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the stock option and incentive plan, exhibits, signatures, and legal opinions. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a capital market filing related to securities registration for employee compensation plans. According to the filing definitions, this type of document corresponds to a Capital/Financing Update (CAP) as it relates to registration of securities for issuance under a stock option plan.
2024-03-01 English
10-K
Annual Report FY 2023
2024-03-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 1, 2024, by Prime Medicine, Inc. It announces the issuance of a press release regarding financial results and business highlights for the quarter and fiscal year ended December 31, 2023. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The text explicitly states that the information is furnished and not filed, indicating it is an announcement rather than the full earnings report. This aligns with the characteristics of an Earnings Release (ER) filing, which is the initial announcement of quarterly or periodical financial results with key highlights only. The document length is 3729 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. Therefore, the appropriate classification is Earnings Release (ER).
2024-03-01 English
SC 13G/A
Major Shareholding Notification
2024-02-29 English
FORM 4
Director's Dealing
2024-02-27 English
FORM 4
Director's Dealing
2024-02-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.